Dr. Tobias Silzle
Medizinische Onkologie und Hämatologie · Dept. I
Covid 19 Impfantwort, Bedarf und Reaktion auf mögliche Booster- Impfung bei Patienten mit soliden Neoplasien
Oct 1, 2021Patienten mit malignen Erkrankungen stellen eine durch die SARS-CoV-2-Pandemie hoch gefährdete Gruppe dar mit einem hohen Hospitalisations- und Mortalitätsrisiko. Eine Impfung gegen SARS-COV2 stellt neben allgemeinen Schutzmassnahmen das wichtigste E...
Clinical Studies - Oct 1, 2021 - Feb 28, 2021
Automatically Closed
Project leader: Fischer Stefanie
Members: Silzle Tobias, Demmer-Steingruber Ruth, Albrich Werner, Kahlert Christian
Response to COVID-19 vaccination and COVID-19 infections after vaccination in patients with haematological malignancies
May 1, 2021The prevalence and mortality of COVID-19 are higher in patients with haematological malignancies (HM) compared to the general population (Vijenthira et al. 2020). Two SARS-CoV-2 messenger RNA (mRNA) vaccines have been approved by Swissmedic, both are...
Clinical Studies - May 1, 2021 - Oct 1, 2022
Completed
Project leader: Silzle Tobias
Members: Fischer Stefanie, Kahlert Christian, Albrich Werner
A Study to Evaluate Imetelstat (GRN163L) in Transfu-sion-Dependent Subjects with IPSS Low or Intermedi-ate-1 Risk Myelodysplastic Syndrome (MDS) that is Re-lapsed/Refractory to Erythropoiesis-Stimulating Agent (ESA) Treatment
Mar 15, 2021A Study to Evaluate Imetelstat (GRN163L) in Transfu-sion-Dependent Subjects with IPSS Low or Intermedi-ate-1 Risk Myelodysplastic Syndrome (MDS) that is Re-lapsed/Refractory to Erythropoiesis-Stimulating Agent (ESA) Treatment
Clinical Studies - Mar 15, 2021 - Apr 7, 2030
Ongoing
Project leader: Silzle Tobias
Members: Driessen Christoph, Fehr Martin, Hitz Felicitas, Lehmann Thomas
Swiss Soliris® and Ultomiris® Reimbursement Registry SSURR: An observational registry for capturing data of patients suffering from paroxysmal nocturnal hemoglobinuria (PNH) who are treated with Soliris® (eculizumab) or Ultomiris® (ravulizumab)
Jan 1, 2021
Clinical Studies - Jan 1, 2021 - Dec 31, 2030
Ongoing
Project leader: Silzle Tobias
Members: Demmer-Steingruber Ruth, Müller Fiona
Lymphopenie bei myeloproliferativen Neoplasien: Prävalenz und prognostische Bedeutung
Jul 1, 2020Eine Lymphopenie als Ausdruck einer Störung des adaptiven Immunsystems ist ein etablierter Risikofaktor bei verschiedenen Allgemein- und Tumorerkrankungen. Im Hinblick auf myeloische Neoplasien konnte im Rahmen eines Kooperationsprojektes des KSSG m...
Clinical Studies - Jul 1, 2020 - Jun 30, 2022
Automatically Closed
Project leader: Silzle Tobias
Members: Messerich Nora-Medea, Cogliatti Sergio B., Lehmann Thomas, Graf Lukas
A Phase 1b/2 Multicenter, Open-label, Expansion Study to As-sess the Safety and Efficacy of AMG 420 as Monotherapy in Subjects With Relapsed and/or Refractory Multiple Myeloma
Dec 5, 2019Bispezifische, T-Zell-aktivierende Antikörper (BITE) sind eine vielversprechende Option, um eine zellvermittelte Immuntherapie von Tumoren zu erreichen. In der vorlie-genden Studie wird die Wirksamkeit und Sicherheit eines gegen das Oberflächenantige...
Clinical Studies - Dec 5, 2019 - Dec 23, 2020
Automatically Closed
Project leader: Driessen Christoph
Members: Silzle Tobias
A Phase 3 Study Comparing Daratumumab, VELCADE (borte-zomib), Lenalidomide, and Dexamethasone (D-VRD) vs VELCADE, Lenalidomide, and Dexamethasone (VRD) in Sub-jects with Previously Untreated Multiple Myeloma who are Eligi-ble for High-dose Therapy
Apr 18, 2019This is a randomized, open-label, multicenter study evalu-ating subjects with newly diagnosed multiple myeloma who are deemed eligible for high-dose therapy. Approximately 690 subjects will be stratified by International Staging Sys-tem (ISS) Stage I...
Clinical Studies - Apr 18, 2019 - Dec 1, 2029
Ongoing
Project leader: Silzle Tobias
Alternate day dosing of Pomalidomide in patients with re-fractory Multiple
Aug 17, 2018Multiple myeloma (MM) accounts for 1% of all cancers and ∼10% of all hematological malignancies. Despite recent advances in myeloma treatment, including the introduction of proteasome inhibitors, immunomodulatory drugs (IMiDs) and stem cell transplan...
Clinical Studies - Aug 17, 2018 - Apr 23, 2023
Automatically Closed
Project leader: Silzle Tobias
An Observatinal Study of Blinatumomab Safety and Effec-tiveness, Utillisation, and Treatment Practice
Jul 11, 2018Study Background and Rationale As a new treatment for acute lymphoblastic leukaemia (ALL), it is important tounderstand the safety and effective-ness of Blincyto (blinatumomab) as it isadministered in routine clinical practice. This study, developed...
Clinical Studies - Jul 11, 2018 - Feb 22, 2022
Automatically Closed
Project leader: Silzle Tobias
Multicentre Oberservational Study of MDS Patients in Switzerland- Swiss MDS Registry
May 17, 2018Die Myelodysplastischen Syndrome (MDS) umfassen eine heterogene Gruppe hämatologischer Stammzellerkran-kungen, welche durch Reifungsstörungen des Knochen-markes (Dysplasien) mit Verminderung der Blutzellen (Zy-topenien) charakterisiert sind. Das Spek...
Clinical Studies - May 17, 2018 - Aug 14, 2030
Ongoing
Project leader: Silzle Tobias
Members: Steiner Marianne
SAKK GRAALL 2014: Multicenter trial for the treatment of Acute Lymphoblastic Leukemia (ALL) in younger adults (18-59 years)
Jun 3, 2016GRAALL-2014 follows the GRAALL-2003 and 2005 trials. The GRAALL-2014 trial is subdivided in three sub-studies: GRAALL-2014/B, GRAALL-2014/T and GRAAPH-2014respectively for patients with B-lineage Ph-negative ALL, T-lineage ALL or Ph+ ALL. France, S...
Clinical Studies - Jun 3, 2016 - May 31, 2026
Ongoing
Project leader: Silzle Tobias
Members: Quinter Janine
Rituximab with or without Ibrutinib for untreated patients with advanced follicular lymphoma in need of therapy. A randomized, double-blinded, SAKK and NLG collaborative Phase II trial
Oct 15, 2015Der Behandlungsansatz beim FL sah bislang entweder ein zunächst abwartendes Beobachten beim asymptomati-schen Patienten oder aber monotherapeutische Behand-lungen vor, mit dem Ziel, möglichst lange eine gute Le-bensqualität zu erhalten. Für die asymp...
Clinical Studies - Oct 15, 2015 - Dec 31, 2029
Ongoing
Project leader: Hitz Felicitas
Members: Silzle Tobias, Fehr Martin, Fischer Stefanie
Combination of ibrutinib and bortezomib followed by ibrutinib maintenance to treat patients with relapsed and refractory mantle cell lymphoma; a multicenter Phase I/II trial
Sep 9, 2015Das Mantelzelllymphom zeichnet sich durch eine für B-Zell Lymphome vergleichsweise schlechte Prognose aus. Dies erklärt sich durch häufige Rückfälle und dem meist ausgedehnten Krankheitsstadium und höherem Alter (median 60-65 Jahre) bei Diagnosestell...
Clinical Studies - Sep 9, 2015 - Mar 31, 2021
Automatically Closed
Project leader: Driessen Christoph
Members: Hitz Felicitas, Fehr Martin, Hess Urs, Hess Dagmar, Silzle Tobias
HOVON 103 / SAKK 30/10 protocol Tosedostat
Mar 19, 2015A randomized phase II multicenter study with a safety run-in to assess the tolerability and efficacy of the addition of oral tosedostat to standard induction therapy in AML and high risk myelodysplasia (MDS) (IPSS-R risk score > 4.5) in patients aged...
Clinical Studies - Mar 19, 2015 - Mar 19, 2015
Automatically Closed
Project leader: Hess Urs
Members: Hitz Felicitas, Baumann Michael, Driessen Christoph, Fehr Martin, Silzle Tobias
Etablierung eines humanisierten Maus-Myelom-Modells
May 1, 2014Das Labor für experimentelle Onkologie befasst sich schwerpunktmässig mit dem Einsatz von Proteasominhibitoren bei der Behandlung des Multiplen Myeloms und anderer hämatologischer Neoplasien. Bisher werden als Modellsystem Monokultur-Systeme unter Ve...
Fundamental Research - May 1, 2014 - Dec 31, 2015
Automatically Closed
Project leader: Driessen Christoph
Members: Silzle Tobias
Entwicklung von Dienstleistungsmodellen der integrierten Onkologie und Palliative Care: Untersuchung von temporalen Aspekten, Involvierung von Onkologen, und Chemotherapie-Gebrauch
Nov 10, 2010Introduction: Integrated models of oncological palliative care are demanded (Ferris JCO 2009) and currently develop in various settings. Patient-data centered descriptions of concrete service patterns (SePa) may serve this process. We aim to explore...
Clinical Studies - Nov 10, 2010 - Oct 31, 2011
Completed
Project leader: Strasser Florian
Members: Silzle Tobias, Nestor Karen, Köberle Dieter, Omlin Aurelius, Blum David, Linder Susanne, Früh Martin
Chart review zur Erfassung typischer Palliative Cancer Care interventionen
Nov 10, 2010Introduction: To evaluate current delivered multidimensional interventions in the context of palliative cancer care, prospective checklist work (Temel NEJM 2010), video-/audio-tape of consultation (Jenkins VA JCO 2011) or retrospective chart reviews...
Clinical Studies - Nov 10, 2010 - Dec 31, 2011
Completed
Project leader: Strasser Florian
Members: Blum David, Nestor Karen, Inauen Roman, Oberholzer Rolf, Silzle Tobias, Rosa Daniel